Skip to main content
OpenTrials
Completed

NCT Number: NCT01129986

A Post Marketing Clinical Study Utilizing DermaStream and Saline in Venous Ulcers

An open-label, prospective, controlled, two-step approach, post-marketing clinical study, applying DermaStream with saline streaming, in conjunction with a sustained multi-compression wrap, on healthy individuals and on patients with a venous stasis ulcer of the lower extremity.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

S.A.L.S.A

Tucson, Arizona, 85724, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Group A:

  • Must be male or female ≥18 years of age.
  • Must be a healthy individual with intact skin

Group B:

  • Must be male or female ≥18 years of age
  • Must have a venous stasis ulcer between the knee and the ankle (including the lateral and medial malleolus). The ulcer must have the typical appearance of venous leg ulceration and the diagnosis of venous origin.
  • Ankle Brachial Pressure Index of >0.8 -<=1.2
  • Must have a venous leg ulcer between 3 cm up to 5.6 cm maximum and an ulcer duration of 60 days or greater prior to enrollment in the study

Exclusion criteria

Group A and Group B:

  • Is unable to manage the self-treatment at home
  • Is pregnant or is a nursing mother
  • Is a woman of child bearing potential who is not using an adequate form of contraception (or abstinent)
  • Is < 18 years of age
  • With gross morbid obesity (i.e., a Body Mass Index ≥ 50)
  • Has a known allergy to any of the drugs and/or dressings that are part of this protocol
  • Has previously participated in this study

Group B:

  • Has an ulcer that is deemed by the Investigator to be caused primarily by a medical condition other than venous insufficiency (e.g., diabetes, malignant ulceration [Marjolin's ulcer], vasculitis, etc.)
  • Has evidence of current clinical infection although colonization is not an exclusion criterion (see definition section)
  • Suffers from diabetes mellitus with HbA1c ≥ 10%
  • Suffers from clinically significant arterial disease
  • Has evidence of the ulcer and/or infection extending to the underlying muscle, tendon, or bone
  • Has used any investigational drug(s)/device(s) within 30 days preceding screening or the physician or subject anticipates use of any of these treatments during the 2 weeks following start of the treatment portion of the study
  • Has used or is anticipated to use any of the prohibited concomitant medications and treatments, as specified in study protocol, section 9.1.
  • Suffers from a condition, other than venous insufficiency or venous hypertension which, in the opinion of the Investigator, would compromise the safety of the subject and/or the quality of the data.
  • Suffers from a condition, other than venous insufficiency or venous hypertension which, in the opinion of the Investigator, would seriously interfere negatively with the normal wound healing process.
  • Has laboratory values at screening outside ± 20% of the institution's normal range for any parameter other than HbA1c
  • If laboratory values are outside ± 20% but the investigator deems the subject acceptable for enrollment, the Principal Investigator may approve the inclusion of the subject as long as there is no evidence of any comorbid condition where comorbidity could influence the trialIs using any of the prohibited concomitant medications or treatments.
  • Wound surrounding skin not intact or has signs of active dermatitis or infection
  • Wound over-bleeds
  • Wound is severely ischemic
  • Wound is larger than device aperture diameter

Treatment and study plan

DermaStream

Device

Five treatment days. On each day DermaStream application for up to 4 hours of saline streaming.

Primary outcomes

  1. Effect of DermaStream application

    Time frame: Up to 21 days

    Reduction of slough tissue.

  2. Adverse Events

    Time frame: Up to 21 days

    Incidence of investigational product related adverse events

  3. Effect of DermaStream application

    Time frame: Up to 21 days

    Increase of granulation tissue

  4. Effect of DermaStream application

    Time frame: Up to 21 days

    Pain recording on 1-10 scale

Secondary outcomes

  1. Usability

    Time frame: 1-5 days

    Device malfunction reports and device replacements as measures of usability

  2. Wound size

    Time frame: Up to 21 days

    Decrease in wound size at 2 weeks following last treatment day

  3. Quality of Life

    Time frame: Up to 21 days

    Improved "Quality of Life" at 2 weeks following last treatment day

Sponsors and collaborators

Lead sponsor

EnzySurge

Industry

Registry information

Official study title

A Post Marketing Clinical Study Utilizing DermaStream and Saline for Safety and Efficacy in Venous Stasis Ulcers of the Lower Extremity

Important dates

Study start
2009
Primary completion
2010
Study completion
2011
First posted
May 25, 2010
Registry last updated
Sep 4, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.